With New Patent, Cesca Eyes Faster, Less Costly CAR-T Cell Production – Genetic Engineering & Biotechnology News
|
With New Patent, Cesca Eyes Faster, Less Costly CAR–T Cell Production
Genetic Engineering & Biotechnology News Chimeric antigen receptor T–cell receptor (CAR-T) and CAR-modified natural killer (CAR-NK) therapeutics can be produced faster and at less cost, Cesca Therapeutics says, through the cellular processing technology covered by a recently-awarded patent. |
